RAB40B, member RAS oncogene familyGenealiases: RAR · SEC4L
Q-omics provides the consensus-scored RAB40B profile across patient tissues and cancer cell-line models. RAB40B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RAB40B is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, RAB40B RNA expression shows 25,392 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, LIHC, and GBM as cancer lineages where RAB40B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB40B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB40B survival associations across molecular data types. RAB40B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB40B RNA expression–survival associations across cancer types. High RAB40B expression shows unfavorable associations in KIRP, BLCA and ESCA, but favorable associations in MESO, SKCM and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RAB40B RNA expression.
This table summarizes RAB40B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RAB40B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB40B shows lower tumor expression in BRCA, KIRC and THCA and higher tumor expression in LIHC, STAD and LUSC. The LIHC box plot shows higher RAB40B RNA expression in tumor versus normal tissue (log2 FC = +0.894, t-test p < 0.001).
This table shows molecular features associated with RAB40B in patient tissues and cancer cell lines. In patient samples, RAB40B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB40B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
